Days after Olumiant became the first JAK inhibitor to be approved in Europe for atopic dermatitis,Eli Lilly and Company and partner Incyte Corporation have presented more positive data on the drug for the skin disease and highlighted its potential as a treatment for alopecia.
The US giant gave little fanfare to the European Commission's approval last week for Olumiant (baricitinib) for the treatment of...






